|
1
|
Ettinger DS, Wood DE, Aisner DL, Akerley
W, Bauman JR, Bharat A, Bruno DS, Chang JY, Chirieac LR, D'Amico
TA, et al: Non-small cell lung cancer, version 3.2022, NCCN
clinical practice guidelines in oncology. J Natl Compr Canc Netw.
20:497–530. 2022. View Article : Google Scholar : PubMed/NCBI
|
|
2
|
Chen P, Liu Y, Wen Y and Zhou C: Non-small
cell lung cancer in China. Cancer Commun (Lond). 42:937–970. 2022.
View Article : Google Scholar : PubMed/NCBI
|
|
3
|
Wei W, Zeng H, Zheng R, Zhang S, An L,
Chen R, Wang S, Sun K, Matsuda T, Bray F and He J: Cancer
registration in China and its role in cancer prevention and
control. Lancet Oncol. 21:e342–e349. 2020. View Article : Google Scholar : PubMed/NCBI
|
|
4
|
Alexander M, Kim SY and Cheng H: Update
2020: Management of non-small cell lung cancer. Lung. 198:897–907.
2020. View Article : Google Scholar : PubMed/NCBI
|
|
5
|
Chen R, Manochakian R, James L, Azzouqa
AG, Shi H, Zhang Y, Zhao Y, Zhou K and Lou Y: Emerging therapeutic
agents for advanced non-small cell lung cancer. J Hematol Oncol.
13:582020. View Article : Google Scholar : PubMed/NCBI
|
|
6
|
Melosky B, Wheatley-Price P, Juergens RA,
Sacher A, Leighl NB, Tsao MS, Cheema P, Snow S, Liu G, Card PB and
Chu Q: The rapidly evolving landscape of novel targeted therapies
in advanced non-small cell lung cancer. Lung Cancer. 160:136–151.
2021. View Article : Google Scholar : PubMed/NCBI
|
|
7
|
Wang X, Zhong D, Zhang J, Du N, Ren Y, Gao
J, Liu L, Yu J, Li X, Ma L, et al: Safety and effectiveness of
apatinib in elderly patients with metastatic gastric cancer: A
sub-analysis from the large-scale, prospective observational study
of apatinib for gastric cancer treatment in a real-world clinical
setting (AHEAD-G202). J Gastrointest Oncol. 13:1679–1689. 2022.
View Article : Google Scholar : PubMed/NCBI
|
|
8
|
Tang Z, Wang Y, Yu Y, Cui Y, Liang L, Xu
C, Shen Z, Shen K, Wang X, Liu T and Sun Y: Neoadjuvant apatinib
combined with oxaliplatin and capecitabine in patients with locally
advanced adenocarcinoma of stomach or gastroesophageal junction: A
single-arm, open-label, phase 2 trial. BMC Med. 20:1072022.
View Article : Google Scholar : PubMed/NCBI
|
|
9
|
Fathi Maroufi N, Rashidi MR, Vahedian V,
Akbarzadeh M, Fattahi A and Nouri M: Therapeutic potentials of
apatinib in cancer treatment: Possible mechanisms and clinical
relevance. Life Sci. 241:1171062020. View Article : Google Scholar : PubMed/NCBI
|
|
10
|
Zhao J, Yu H, Han T, Wang W, Tong W and
Zhu X: A study on the efficacy of recombinant human endostatin
combined with apatinib mesylate in patients with middle and
advanced stage non-small cell lung cancer. J BUON. 24:2267–2272.
2019.PubMed/NCBI
|
|
11
|
Hu R, Li T, Hui K, Chen Z, Wang N, Wu X,
Ge L and Zhou L: Apatinib sensitizes chemoresistant NSCLC cells to
doxetaxel via regulating autophagy and enhances the therapeutic
efficacy in advanced and refractory/recurrent NSCLC. Mol Med Rep.
22:3935–3943. 2020.PubMed/NCBI
|
|
12
|
Xu J, Liu X, Yang S, Zhang X and Shi Y:
Clinical response to apatinib monotherapy in advanced non-small
cell lung cancer. Asia Pac J Clin Oncol. 14:264–269. 2018.
View Article : Google Scholar : PubMed/NCBI
|
|
13
|
Guo Y and Jing X: Efficacy and safety of
docetaxel plus apatinib as a second-line treatment for advanced
nonsquamous non-small cell lung cancer. Chin J Clin Oncol.
44:544–546. 2017.
|
|
14
|
Chen E, Chen Z, Chen M and Che M: Clinical
effect evaluation of apatinib mesylate tablets in the treatment of
advanced non-small cell lung cancer. China Mod Med. 24:91–93.
2017.
|
|
15
|
Liu X and Zheng J: Curative effect of
second-line chemotherapy of apatinib combined with docetaxel on
advanced non-squamous non-small-cell lung cancer. Pract J Card
Cereb Pneumal Vasc Dis. 26:104–107. 2018.
|
|
16
|
Shang K, Hu R and Hu J: Effects of
apatinib combined with docetaxel on CEA, SCC and CA125 in
second-line treatment of patients with advanced non-small cell lung
cancer. Pract J Cancer. 34:1172–1175. 2019.
|
|
17
|
Luo R and Li B: Clinical effect of
apatinib combined with chemotherapy on patients with advanced
non-small cell lung cancer after failure of first-line treatment.
Oncol Prog. 17:1809–1812. 2019.
|
|
18
|
Yu Z, Cai X, Xu Z, He Z, Lai J, Wang W,
Zhang J, Kong W, Huang X, Chen Y, et al: Apatinib plus chemotherapy
as a second-line treatment in unresectable non-small cell lung
carcinoma: A randomized, controlled, multicenter clinical trial.
Oncologist. 25:e1640–e1649. 2020. View Article : Google Scholar : PubMed/NCBI
|
|
19
|
Guo C, Dong J, Yin Y, Cui J, Gao Y and
Zhang J: The efficacy and safety of apatinib combined with
chemotherapy in the first-line treatment of driver-negative
advanced non-small cell lung cancer. Syst Med. 5:10–12. 2020.
|
|
20
|
Xie MQ, Wen B, Xu HX and Song YR: Efficacy
of apatinib combined with cisplatin and paclitaxel in the treatment
of driver gene wild-type advanced non-squamous non-small cell lung
cancer. J Basic Clin Oncol. 33:198–200. 2020.
|
|
21
|
Li S: Effect of Apatinib mesylate tablets
combined with paclitaxel injection on the efficacy of patients with
non-small cell lung cancer. Contemp Med. 26:175–177. 2020.
|
|
22
|
Cui YJ, Liu J, Liu MM and Zhang HZ:
Observation on the clinical effect of apatinib combined with
chemotherapy in the treatment of advanced non-small cell lung
cancer. Pak J Med Sci. 37:1036–1041. 2021. View Article : Google Scholar : PubMed/NCBI
|
|
23
|
Chen P, Chen W and Zhang J: Efficacy,
safety and prognosis of apatinib plus docetaxel compared with
docetaxel in the second line treatment in advanced non-squamous
non-small cell lung cancer. J Mod Oncol. 29:1513–1519. 2021.
|
|
24
|
Huang Y, Lin Q, You X, Cao X and Li W:
Clinical effects of apatinib in combination with cisplatin and
paclitaxel chemotherapy for advanced non-small cell lung cancer. J
Math Med. 34:1669–1671. 2021.
|
|
25
|
Liu J, Pan X and Zheng G: Efficacy of
apatinib mesylate in combination with paclitaxel in advanced
non-small cell lung cancer and the effect on serum tumor markers.
Shanxi Med J. 50:784–786. 2021.
|
|
26
|
Guo H: Clinical effect of apatinib
mesylate tablets combined with chemotherapy for advanced non-small
cell lung cancer. Med Forum. 25:3204–3206. 2021.
|
|
27
|
Song Y, Zhao Q and Lv J: Effect of
apatinib combined with chemotherapy on multiple tumor markers in
patients with advanced non-small cell lung cancer and its
short-term efficacy. Int J Pathol Clin Med. 41:2824–2829. 2021.
|
|
28
|
Chen L, Zhou L, Jin X, Ma S and Jiang X:
Efficacy analysis of apatinib combined with paclitaxel and
cisplatin in the treatment of non-small cell lung cancer. World J
Complex Med. 8:187–190. 1982022.
|
|
29
|
Lu M: Effects of apatinib combined with
paclitaxel in treatment of elderly patients with advanced non-small
cell lung cancer. Med J Chin People's Health. 34:28–31. 2022.
|
|
30
|
Li Z, Liu Z, Wu Y, Li H, Sun Z, Han C,
Zhang X and Zhang J: Efficacy and safety of apatinib alone or
apatinib plus paclitaxel/docetaxel versus paclitaxel/docetaxel in
the treatment of advanced non-small cell lung cancer: A
meta-analysis. Thorac Cancer. 12:2838–2848. 2021. View Article : Google Scholar : PubMed/NCBI
|
|
31
|
Higgins JP, Altman DG, Gøtzsche PC, Jüni
P, Moher D, Oxman AD, Savovic J, Schulz KF, Weeks L, Sterne JA, et
al: The cochrane collaboration's tool for assessing risk of bias in
randomised trials. BMJ. 343:d59282011. View Article : Google Scholar : PubMed/NCBI
|
|
32
|
Wells GA, Shea B, O'Connell D, Peterson J,
Welch V, Losos M and Tugwell P: The Newcastle-Ottawa Scale (NOS)
for assessing the quality of nonrandomised studies in
meta-analyses. 2000.
|
|
33
|
Pang LL, Gan JD, Huang YH, Liao J, Zhuang
WT, Ali WA, Hong SD, Zhang L and Fang WF: Role of antiangiogenic
agents in first-line treatment for advanced NSCLC in the era of
immunotherapy. BMC Cancer. 23:722023. View Article : Google Scholar : PubMed/NCBI
|
|
34
|
Manzo A, Montanino A, Carillio G, Costanzo
R, Sandomenico C, Normanno N, Piccirillo MC, Daniele G, Perrone F,
Rocco G and Morabito A: Angiogenesis inhibitors in NSCLC. Int J Mol
Sci. 18:20212017. View Article : Google Scholar : PubMed/NCBI
|
|
35
|
Zhang H: Apatinib for molecular targeted
therapy in tumor. Drug Des Devel Ther. 9:6075–6081. 2015.
View Article : Google Scholar : PubMed/NCBI
|
|
36
|
Feng J and Qin S: The synergistic effects
of Apatinib combined with cytotoxic chemotherapeutic agents on
gastric cancer cells and in a fluorescence imaging gastric cancer
xenograft model. Onco Targets Ther. 11:3047–3057. 2018. View Article : Google Scholar : PubMed/NCBI
|
|
37
|
Wei B, Wang Y, Wang J, Cai X, Xu L, Wu J,
Wang Y, Liu W, Gu Y, Guo W and Xu Q: Apatinib suppresses tumor
progression and enhances cisplatin sensitivity in esophageal cancer
via the Akt/β-catenin pathway. Cancer Cell Int. 20:1982020.
View Article : Google Scholar : PubMed/NCBI
|
|
38
|
Shi J, Yang H, Lv T, Pan H and Yang B:
Efficacy of platinum drugs in the treatment of elderly patients
with advanced non-small cell lung cancer and their effects on
prognosis and survival. J BUON. 25:1737–1744. 2020.PubMed/NCBI
|
|
39
|
Ferrara R, Imbimbo M, Malouf R,
Paget-Bailly S, Calais F, Marchal C and Westeel V: Single or
combined immune checkpoint inhibitors compared to first-line
platinum-based chemotherapy with or without bevacizumab for people
with advanced non-small cell lung cancer. Cochrane Database Syst
Rev. 4:CD0132572021.PubMed/NCBI
|
|
40
|
Li J, Qin S, Xu J, Xiong J, Wu C, Bai Y,
Liu W, Tong J, Liu Y, Xu R, et al: Randomized, double-blind,
placebo-controlled phase III trial of apatinib in patients with
chemotherapy-refractory advanced or metastatic adenocarcinoma of
the stomach or gastroesophageal junction. J Clin Oncol.
34:1448–1454. 2016. View Article : Google Scholar : PubMed/NCBI
|
|
41
|
Geng R, Song L, Li J and Zhao L: The
safety of apatinib for the treatment of gastric cancer. Expert Opin
Drug Saf. 17:1145–1150. 2018. View Article : Google Scholar : PubMed/NCBI
|
|
42
|
Knezevic CE and Clarke W: Cancer
chemotherapy: The case for therapeutic drug monitoring. Ther Drug
Monit. 42:6–19. 2020. View Article : Google Scholar : PubMed/NCBI
|
|
43
|
Li C, Ma L, Wang Q, Shao X, Guo L, Chen J,
Wang W and Yu J: Rho kinase inhibition ameliorates vascular
remodeling and blood pressure elevations in a rat model of
apatinib-induced hypertension. J Hypertens. 40:675–684. 2022.
View Article : Google Scholar : PubMed/NCBI
|
|
44
|
Xia H, Zhou C, Luo Z, Zhang P, Zhu L and
Gong Z: Apatinib-induced hand-foot skin reaction in chinese
patients with liver cancer. Front Oncol. 11:6243692021. View Article : Google Scholar : PubMed/NCBI
|
|
45
|
Botrel TE, Clark O, Clark L, Paladini L,
Faleiros E and Pegoretti B: Efficacy of bevacizumab (Bev) plus
chemotherapy (CT) compared to CT alone in previously untreated
locally advanced or metastatic non-small cell lung cancer (NSCLC):
Systematic review and meta-analysis. Lung Cancer. 74:89–97. 2011.
View Article : Google Scholar : PubMed/NCBI
|
|
46
|
Zhang S, Mao XD, Wang HT, Cai F and Xu J:
Efficacy and safety of bevacizumab plus erlotinib versus
bevacizumab or erlotinib alone in the treatment of non-small-cell
lung cancer: A systematic review and meta-analysis. BMJ Open.
6:e0117142016. View Article : Google Scholar : PubMed/NCBI
|
